ATE323691T1 - Meglumin salz einer spezifischen quinolinsaeure verbindung mit nmda rezeptor-aktivität - Google Patents

Meglumin salz einer spezifischen quinolinsaeure verbindung mit nmda rezeptor-aktivität

Info

Publication number
ATE323691T1
ATE323691T1 AT00983240T AT00983240T ATE323691T1 AT E323691 T1 ATE323691 T1 AT E323691T1 AT 00983240 T AT00983240 T AT 00983240T AT 00983240 T AT00983240 T AT 00983240T AT E323691 T1 ATE323691 T1 AT E323691T1
Authority
AT
Austria
Prior art keywords
specific
acid compound
receptor activity
nmda receptor
quinolinic acid
Prior art date
Application number
AT00983240T
Other languages
English (en)
Inventor
Alessandra Orlandi
Original Assignee
Glaxosmithkline Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Spa filed Critical Glaxosmithkline Spa
Application granted granted Critical
Publication of ATE323691T1 publication Critical patent/ATE323691T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT00983240T 1999-12-08 2000-12-07 Meglumin salz einer spezifischen quinolinsaeure verbindung mit nmda rezeptor-aktivität ATE323691T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9929037.1A GB9929037D0 (en) 1999-12-08 1999-12-08 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
ATE323691T1 true ATE323691T1 (de) 2006-05-15

Family

ID=10865952

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983240T ATE323691T1 (de) 1999-12-08 2000-12-07 Meglumin salz einer spezifischen quinolinsaeure verbindung mit nmda rezeptor-aktivität

Country Status (30)

Country Link
US (2) US6713491B2 (de)
EP (1) EP1237886B1 (de)
JP (1) JP4311901B2 (de)
KR (1) KR100788579B1 (de)
CN (1) CN1325488C (de)
AR (1) AR030923A1 (de)
AT (1) ATE323691T1 (de)
AU (1) AU769232B2 (de)
BR (1) BR0016235A (de)
CA (1) CA2393303C (de)
CO (1) CO5251474A1 (de)
CY (1) CY1106105T1 (de)
CZ (1) CZ301052B6 (de)
DE (1) DE60027461T2 (de)
DK (1) DK1237886T3 (de)
ES (1) ES2257343T3 (de)
GB (1) GB9929037D0 (de)
HK (1) HK1047436B (de)
HU (1) HUP0203650A3 (de)
IL (2) IL150010A0 (de)
MX (1) MXPA02005802A (de)
MY (1) MY129892A (de)
NO (1) NO323263B1 (de)
PL (1) PL356713A1 (de)
PT (1) PT1237886E (de)
TN (1) TNSN00240A1 (de)
TR (1) TR200201503T2 (de)
TW (1) TW524804B (de)
WO (1) WO2001042238A1 (de)
ZA (1) ZA200204492B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004234235A1 (en) 2003-04-25 2004-11-11 Nippon Chemiphar Co., Ltd. Salt of (2s,3s)-3-[[(1s)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
US7576216B2 (en) 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
US7728143B2 (en) * 2004-10-08 2010-06-01 Abbott Laboratories Salt and crystalline forms thereof of a drug
SI1868581T1 (sl) * 2005-04-11 2012-06-29 Abbott Lab Farmacevtski sestavki z izboljšanim profilom topnosti za slabo topna zdravila
ES2818977T3 (es) * 2011-10-25 2021-04-14 Janssen Pharmaceutica Nv Método para obtener cristales de sal de meglumina de ácido 1-(5,6-dicloro-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
US6413959B1 (en) * 1995-04-14 2002-07-02 Boehringer Ingelheim Kg Method of treating depression with arylglycinamide derivatives
CZ292379B6 (cs) 1995-09-29 2003-09-17 Glaxo Wellcome Spa Tetrahydrochinolinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
CA2393303C (en) 2009-10-20
IL150010A0 (en) 2002-12-01
PL356713A1 (en) 2004-06-28
HK1047436B (en) 2006-07-21
CZ301052B6 (cs) 2009-10-21
TR200201503T2 (tr) 2002-10-21
DK1237886T3 (da) 2006-08-14
US6943176B2 (en) 2005-09-13
KR20020086854A (ko) 2002-11-20
NO20022682L (no) 2002-07-17
CO5251474A1 (es) 2003-02-28
NO323263B1 (no) 2007-02-19
MY129892A (en) 2007-05-31
US6713491B2 (en) 2004-03-30
CY1106105T1 (el) 2011-06-08
JP4311901B2 (ja) 2009-08-12
AU2006001A (en) 2001-06-18
HUP0203650A2 (hu) 2003-03-28
HUP0203650A3 (en) 2004-01-28
WO2001042238A1 (en) 2001-06-14
ZA200204492B (en) 2004-06-30
NO20022682D0 (no) 2002-06-06
JP2003516403A (ja) 2003-05-13
HK1047436A1 (en) 2003-02-21
CA2393303A1 (en) 2001-06-14
IL150010A (en) 2009-09-01
TW524804B (en) 2003-03-21
DE60027461D1 (de) 2006-05-24
AU769232B2 (en) 2004-01-22
PT1237886E (pt) 2006-07-31
TNSN00240A1 (en) 2002-05-30
CZ20021981A3 (cs) 2003-01-15
ES2257343T3 (es) 2006-08-01
KR100788579B1 (ko) 2007-12-26
CN1407980A (zh) 2003-04-02
MXPA02005802A (es) 2004-08-12
EP1237886B1 (de) 2006-04-19
US20040162313A1 (en) 2004-08-19
US20030008899A1 (en) 2003-01-09
GB9929037D0 (en) 2000-02-02
DE60027461T2 (de) 2006-09-28
CN1325488C (zh) 2007-07-11
EP1237886A1 (de) 2002-09-11
BR0016235A (pt) 2002-08-27
AR030923A1 (es) 2003-09-03

Similar Documents

Publication Publication Date Title
ATE320799T1 (de) Retardierte, orale, pharmazeutische darreichnungsformen mit tramadol
NO2013004I1 (no) axitinib, valgfritt i form av et farmasøytisk aksentabelt salt
DE69926597D1 (de) Spender mit automatisch gespeister Auftragsvorrichtung
DK0981527T3 (da) Salt af et naphthyridincarboxylsyrederivat
FI970547L (fi) Retinohapon X-reseptoriligandit
DK1189916T3 (da) N-pyrazol A 2A-receptoragonister
NO983624D0 (no) Biocid preparat i fast form
EE9900550A (et) S-omeprasooli uus vorm
NO994091D0 (no) Medisinsk preparat inneholdende en lipofilisk intergass
DE50002778D1 (de) Verbindung
TR199802528A3 (tr) Bir katalizörün hazirlanmasi için bir islem.
FI944035L (fi) Tramadolisuolaa sisältävä lääkeaine, jolla on viivästynyt vaikuttavan aineen vapautuminen
DE69520347D1 (de) Borsäure-Verbindungen mit einer Binaphthyl-Gruppe
DE69930643D1 (de) Impulsgeber mit flächiger spule
IL137594A0 (en) Implementing selective shared-intervention protocol for a system with multi-processor nodes
NO20000248L (no) Intelligent produksjonsstigerør
NO2011004I1 (no) Emamectin eller et salt derav, særlig emamectinbenzosyresalt
DE60101562D1 (de) Spender mit einer förderspule
DE50005284D1 (de) Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate mit antitumorwirkung
DE69932096D1 (de) Geschoss mit einer halb-weichen spitze
DE60039190D1 (de) Massnahmen welche die effekte einer kalorischen beschränkung nachahmen
DE60027461D1 (de) Meglumin salz einer spezifischen quinolinsaeure verbindung mit nmda rezeptor-aktivität
AU2001277536A1 (en) 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity
AU2001243630A1 (en) 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr)receptors
AU6221201A (en) Propanoic acid derivatives as integrin receptor antagonists

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1237886

Country of ref document: EP